Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy

Kidney and Blood Pressure Research

Volumn 30, Issue 4, 2007, Pages 203-211

  Jin, Hui Min ^a   Pan, Yu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

End stage renal disease; Losartan; Pioglitazone; Proteinuria; Type 2 diabetic nephropathy

Indexed keywords

GLUCOSE; INSULIN; LOSARTAN; PENTETATE TECHNETIUM TC 99M; PIOGLITAZONE;

ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG TOLERABILITY; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENOGRAPHY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 34447530707     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104089     Document Type: Article

References (33)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
3. Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K: Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rats. Metabolism 2002;51:403-408.
4. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E, Demura H: Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997;272(6 Pt 1):E989-E96.
5. Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, Tomino Y: Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004;53:1473-1479.
6. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H: Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001;50:1193-1196.
7. Katavetin P, Eiam-Ong S, Suwanwalaikorn S: Pioglitazone reduces urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. J Med Assoc Thai 2006;89:170-177.
8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
9. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70:536-542.
10. Sarafidis PA, Bakris GL: Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006;70:1223-1233.
11. Hanefeld M, Brunetti P, Schernthaner G, Matthews DR, Charbonnel B; QUARTET Study Group: One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-147.
12. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; QUARTET Study Group: Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-6076.
13. Charbonnel B, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; QUARTET Study Group: A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, doubleblind, parallel-group comparison trial. Diabet Med 2005;22:399-405.
14. Dong FQ, Li H, Cai WM, Tao J, Li Q, Ruan Y, Zheng FP, Zhang Z: Effects of pioglitazone on expression of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J (Engl) 2004;117:1040-1044.
15. Isshiki K, Haneda M, Kova D, Maeda S, Sugimoto T, Kikkawa R: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-1032.
16. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H: Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000;14:250-254.
17. Agarwal R, Saha C, Battiwala M, Vasavada N, Curlev T, Chase SD, Sachs N, Semret MH: A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005;68:285-292.
18. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799-812.
19. Ruiz-Ortega M, Rupérez M, Esteban V, Rodríguez-Vita J, Sánchez-López E, Carvajal G, Egido J: Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 2006;21:16-20.
20. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, Dolf W, Rutledge J: Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs. Physiol Genomics 2002;11:21-30.
21. Chen K, Chen J, Li D, Zhang X, Mehta J: Angiotensin II regulation of collagen type 1 expression in cardiac fibroblasts: modulation by PPAR-γ ligand pioglitazone. Hypertension 2004;44:655-661.
22. Benkirane K, Amiri F, Diep QN, EI Mabrouk M, Schiffrin EL: PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4EBP1. Am J Physiol Heart Circ Physiol 2006;290:H390-H397.
23. Benkirane K, Viel EC, Amiri F, Schiffrin EL: Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 2006;47:102-108.
24. Diep QN, EI Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 2002;105:2296-2302.
25. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-γ activated receptor is a negative regulator of macrophage activation. Nature 1998;391:79-82.
26. Majithiya JB, Parmar AN, Trivedi CJ, Balaraman R: Effect of pioglitazone on L-NAME induced hypertension in diabetic rats. Vascul Pharmacol 2005;43:260-266.
27. Gumieniczek A: Effect of the new thiazolidinedione pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 2003;74:553-562.
28. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M: Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004;53:200-208.
29. Rigalleau V, Lasseur C, Raffaitin C, Perlemoine C, Barthe N, Chauveau P, Combe C, Gin H: Glucose control influences glomerular filtration rate and its prediction in diabetic subjects. Diabetes Care 2006;29:1491-1495.
30. Chujo K, Shima K, Tada H, Oohashi T, Minakuchi J, Kawashima S: Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J Med Invest 2006;53:223-228.
31. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM: Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006;70:1503-1509.
32. Physician's Desk Reference: Pioglitazone. Montvale, Thomson PDR, 2005, p 3185.
33. Gillies PS, Dunn CJ: Pioglitazone. Drugs 2000;60:344-345.